高级搜索
孟文静, 佟仲生. HER2基因突变在乳腺癌治疗中的研究进展[J]. 肿瘤防治研究, 2023, 50(2): 191-194. DOI: 10.3971/j.issn.1000-8578.2023.22.0769
引用本文: 孟文静, 佟仲生. HER2基因突变在乳腺癌治疗中的研究进展[J]. 肿瘤防治研究, 2023, 50(2): 191-194. DOI: 10.3971/j.issn.1000-8578.2023.22.0769
shu
MENG Wenjing, TONG Zhongsheng. Research Progress of HER2 Gene Mutation in Treatment of Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(2): 191-194. DOI: 10.3971/j.issn.1000-8578.2023.22.0769
Citation: MENG Wenjing, TONG Zhongsheng. Research Progress of HER2 Gene Mutation in Treatment of Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(2): 191-194. DOI: 10.3971/j.issn.1000-8578.2023.22.0769
shu

HER2基因突变在乳腺癌治疗中的研究进展

Research Progress of HER2 Gene Mutation in Treatment of Breast Cancer

    摘要
  • 摘要: 人表皮生长因子受体2（HER2）是一种酪氨酸激酶受体，是乳腺癌治疗的主要药物靶点和临床生物标志物。大约2%的乳腺癌存在HER2突变。无论HER2表达水平或扩增状态如何，有HER2突变的乳腺癌都可能对靶向HER2治疗有反应，因此本文对HER2基因突变在乳腺癌治疗中的研究进展进行梳理和综述。

     

    Abstract: HER2 is a tyrosine kinase receptor. It is the main drug target and clinical biomarker for the treatment of breast cancer. About 2% of breast cancer cases has HER2 mutations. Regardless of the expression level or amplification status of HER2, breast cancer with HER2 mutations may respond to targeted HER2 therapy. This article reviews the research progress of HER2 gene mutation in the treatment of breast cancer.

     

    • HTML全文
    • 参考文献(22)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回

This work is licensed under a Creative Commons Attribution 3.0 License.

邮件订阅 RSS
总访问量： 今日访问：